Back to School: How biopharma can reboot drug development. Access exclusive analysis here

VBL falls on Phase III glioblastoma miss

Vascular Biogenics Ltd. (NASDAQ:VBLT) was off $4.15 (61%) to $2.65 on Thursday, losing over $120 million in market cap, after reporting that ofranergene obadenovec (VB-111) missed the

Read the full 271 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE